top of page

$10.4 Million Revenue Pharm & Biotech Consulting Firm

Listing Code:

PACS1B

State:

California

Category:

Consultants, Care Management, & Fiduciary

Asking Price:

$14,000,000

Revenue:

$10,400,000

PACS1B
Company Overview

PRIME exits and American HealthCare Capital are pleased to introduce a Pharmaceutical and Biotech Consulting firm for sale located in Pennsylvania and California. Founded in 1993, the business is a statistical consulting firm whose clients consist of pharmaceutical and biotech companies. The Company specializes in supporting statistical data analysis and reporting for clinical research, and they are a key player in assisting pharma companies to win new drug approvals from the FDA. 

Financial Overview

The business has increased the top and bottom line over the past several years. In the year ending 2019, total revenue was $5.258 million with an EBITDA of $873,000. In the pandemic year of 2020, the company accomplished a 15% growth rate to a total revenue of $6.045 million and an EBITDA of $826,000. The next two years, 2021 and 2022, the business had its best back-to-back years with 26% and 25% growth respectively. The company ended 2021 with $7.614 million in total sales with an EBITDA of $997,000. In the year ending 2022, total sales were $8.951 million with an EBITDA of $1.58 million. The year ending 2023 showed an increased total revenue to $10.4 Million with a year ending EBITDA of $1.7 Million. Based upon the projected YE Revenue for 2024, the company is anticipating a Total Revenue of $11.5 million with an EBITDA of $1.85 Million. 

Staff Overview

The current owner is pursuing the sale to semi-retire and concentrate on other businesses he has ownership in. To facilitate a successful and orderly transition, he is willing to remain with the Company during a transitional period. He will ensure that the new buyers have met all the key clients and understand the operations’ day-to-day function. The owner is also open to staying on as a consultant or part-time employee if needed after the transition. 

Asking Price

The asking price for this pharmaceutical and biotech consulting firm is $14 million.

Inquire About This Listing:

In order to learn more about our listing, you must:

1. Complete a Buyer Profile:

This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.

YOU ONLY NEED TO COMPLETE A BUYER PROFILE ONCE. 

2. Sign NDA with Listing Code:

To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.

Listing Code:

PACS1B

Listing Title:

$10.4 Million Revenue Pharm & Biotech Consulting Firm

Heading 4

Contact the Team

Jack Eskenazi American Healthcare Capital

Jack Eskenazi

President/Founder

American HealthCare Capital

Dr. Allen Nazeri DDS MBA.jpg

Dr. Allen Nazeri 

Managing Partner

PRIME exits

Join our mailing list to receive our latest news, and listings.

Thanks for submitting!

bottom of page